HTA Methodological Shifts & Pricing Pressures

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are hitting at some of the most pressing structural tensions in the system right now.

MarcusExactly. We're looking at CMS Part D redesign implementation challenges — why the operational hurdles are reshaping market access timelines. Then EMA's adaptive licensing expansion for rare diseases — what the scaled-up framework signals for development pathways. NICE's threshold consultation implications — how the proposed £50k ceiling could redefine cost-effectiveness benchmarks. And FDA's RWE guidance for accelerated approvals — why the draft framework is forcing evidence strategy recalibration.

SaraThat first one resonates — the Part D redesign isn't just administrative; it's creating real-world bottlenecks in formulary negotiations that are delaying patient access.

MarcusLet's get into it.

MarcusStarting with CMS Part D redesign implementation challenges. The operational hurdles are reshaping market access timelines significantly. What we're seeing is a cascade of delays in formulary submissions and coverage determinations as plans grapple with the new structure. This isn't just procedural noise; it's creating tangible access barriers for patients.

SaraAbsolutely. And from a payer perspective, the real friction point is the rebate reconciliation mechanics. Plans are now bearing more upfront risk without clear pathways for clawbacks when utilization exceeds projections. That budget uncertainty is translating into more conservative coverage decisions.

MarcusThat connects to something I keep coming back to — the redesign's impact on HEOR evidence generation timelines. Companies are having to submit data earlier in the process, but the evidence requirements are evolving faster than many evidence strategies can adapt. What strikes me is how this is compressing the window for RWE generation.

SaraI wonder if that's the full picture though. The part that gives me pause is the lack of standardized metrics for performance-based contracting. Plans are developing their own KPIs, which creates patchwork evidence requirements that make cross-jurisdictional value demonstrations incredibly complex.

MarcusThat's fair. And what's interesting is that this fragmentation is pushing some manufacturers toward more real-world data pilots to demonstrate value under different plan structures. But that creates its own resource challenges.

SaraExactly. The budget impact question there is one the field hasn't fully worked out yet. How do you model value when the payment structures themselves are in flux?

MarcusRight. And we're seeing some innovative approaches, like outcome-based agreements tied to specific Part D quality measures. But the implementation gap between design and execution remains significant.

SaraShifting to EMA's adaptive licensing expansion for rare diseases. The scaled-up framework signals a major shift in development pathways, particularly for ultra-orphan conditions. What's particularly noteworthy is how they're integrating post-authorization data requirements earlier in the process.

MarcusAbsolutely. And this is one area where innovation and access align beautifully. The expanded pathway acknowledges the evidence constraints in rare diseases while maintaining scientific rigor. What I find compelling is how it's enabling earlier HTA engagement through the joint clinical assessment mechanism.

SaraThat's one read — I'd frame it slightly differently. The part that gives me pause is the tension between accelerated timelines and the depth of real-world evidence being generated. Are we rushing to fill evidence gaps with surrogate endpoints that may not capture meaningful patient benefit?

MarcusThat's a valid concern. But what strikes me is how the adaptive framework actually mandates more robust post-marketing surveillance than traditional pathways. The requirement for confirmatory studies isn't being relaxed; it's being restructured to fit rare disease realities.

SaraThe methodology question remains though. How do HTA bodies assess cost-effectiveness when the evidence base is inherently probabilistic? That's where I see the biggest operational challenge emerging.

MarcusExactly. And it's forcing HEOR teams to develop more sophisticated probabilistic modeling approaches that can handle uncertainty at every stage. The good news is that it's driving innovation in value demonstration techniques.

SaraStill, the budget impact question looms large. When you have therapies with ultra-high prices but ultra-small populations, how do you demonstrate system value? That's the elephant in the room.

MarcusAgreed. And we're seeing some creative approaches, like managed entry agreements with milestone payments tied to real-world outcomes. But the implementation complexity is substantial.

MarcusNow to NICE's threshold consultation implications. The proposed £50k ceiling could redefine cost-effectiveness benchmarks across the board. What's particularly significant is how they're explicitly linking it to societal value and health equity considerations.

SaraThat's the headline, but I'm more interested in the operational implications. The consultation suggests they're moving toward a more flexible thresholding system, which could create significant unpredictability for manufacturers. How do you build a pricing strategy when the benchmark itself is variable?

MarcusThat connects to something I've been tracking — the increasing emphasis on equity weighting in their decision framework. This isn't just about QALYs anymore; it's about who benefits and how. What strikes me is how this aligns with broader value-based healthcare trends.

SaraI'd push back slightly on that. While equity considerations are important, the practical implementation is creating methodological headaches. How do you quantify the value of addressing health disparities in a way that's consistent across different disease areas? That's where the field is struggling.

MarcusThat's a fair point. And what's interesting is how this is driving more nuanced value demonstration strategies. Companies are having to develop evidence packages that explicitly address equity considerations, which requires deeper patient engagement.

SaraExactly. The part that gives me pause is the potential for inconsistency. If different committees apply equity weights differently, we could end up with patchy access decisions based on subjective judgments rather than objective evidence.

MarcusThat's a valid concern. But I'm encouraged by how NICE is trying to standardize this through their equity assessment framework. The challenge will be implementation consistency.

SaraFinally, FDA's RWE guidance for accelerated approvals. The draft framework is forcing evidence strategy recalibration across the industry. What's particularly noteworthy is how they're explicitly acknowledging RWE's role in confirming clinical benefit.

MarcusAbsolutely. This represents a significant shift from the traditional reliance on randomized controlled trials. What I find compelling is how it's creating opportunities for more efficient evidence generation using real-world data sources.

SaraThat's one read — I'd frame it slightly differently. The part that gives me pause is the methodological rigor question. How do you ensure that RWE studies can truly establish causal relationships when confounding factors are inherent in real-world settings? That's the fundamental challenge.

MarcusThat's a fair concern. But what strikes me is how the guidance emphasizes methodological robustness through careful study design and advanced analytical techniques. They're not lowering standards; they're expanding the toolkit for meeting them.

SaraStill, the payer perspective remains skeptical. We've seen too many RWE studies that couldn't withstand scrutiny when it came to formulary decisions. How do we build confidence in these approaches?

MarcusThat's where the draft guidance's emphasis on transparency and reproducibility comes in. By requiring detailed methodology documentation and independent validation, they're trying to address those trust issues.

SaraThe operational burden is substantial though. Companies will need significant resources to generate RWE that meets these new standards. That could widen the gap between large and small manufacturers.

MarcusThat's an important point. But I'm optimistic that this will drive innovation in RWE methodologies, ultimately benefiting the entire ecosystem.

SaraA lot to think about today. I'll be watching how the Part D redesign implementation challenges evolve, particularly the rebate mechanics and their impact on coverage decisions.

MarcusSame — and for me the thread running through today is how regulatory and HTA frameworks are increasingly converging around real-world evidence and value demonstration. That's where the future of market access is heading.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.